GlycoT awarded a Phase I SBIR

April 28, 2022

GlycoT was awarded a Phase I SBIR titled "Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation" (1/R43GM146537) with total funding support of $321,239.

Research and Development Collaborations
To request a quote for our products, customized service, investment opportunities, or if you have any general inquiry for our company click the start now button.
Learn More